Furthermore, a meta-analysis of five Phase III randomized controlled trials on esophageal cancer showed that once the PD-L1 CPS is 10 or above, there is a marked augmentation in the patients’ PFS (57). This evidence concerns the gene CD274 and esophageal cancer.